Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vilamakitug - XBiotech

Next Previous
X
Search
Drug Profile

Vilamakitug - XBiotech

Alternative Names: Natrunix; Natrunix-SQ; XB-2001

Latest Information Update: 05 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XBiotech
  • Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Colorectal cancer; Rheumatoid arthritis
  • Phase I Arthritis

Most Recent Events

  • 31 Jul 2024 XBiotech plans a phase II trial for Axial spondyloarthritis (Treatment-naive) (IV) in August 2024 (NCT06526377)
  • 18 Jun 2024 Efficacy and adverse events data from the phase I/II 1-BETTER trial in Pancreatic cancer released by XBiotech
  • 10 Jun 2024 XBiotech completes the phase-I/II 1-BETTER trial in Pancreatic cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (IV) (NCT04825288)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top